Presentation @ESRD summit

On June 18th, our CEO Dr. Michael Wilke was invited to present a new study that we just completed. It is a cost comparison of endovascular vs. surgical arteriovenous fistulas for dialysis (endoAVF vs. surgical AVF).
The study was using the data from the NEAT trial and routine data from german health insurance. EndoAVF has significantly less post-procedure complications and therefore is cost-effective compared to surgical AVF.
This is an important result also for german payors, as now it is proven that the new procedure is not inefficient.